<DOC>
	<DOCNO>NCT02539966</DOCNO>
	<brief_summary>The FANTOM II trial intend assess safety performance Fantom Bioresorbable Coronary Scaffold native coronary artery .</brief_summary>
	<brief_title>Safety &amp; Performance Study FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patient evidence myocardial ischemia positive functional study Target lesion visually estimate stenosis ≥50 % &lt; 100 % Target lesion locate native coronary artery average reference vessel diameter ≥ 2.5mm ≤ 3.5mm Target lesion length must ≤ 20mm Baseline TIMI flow ≥ 2 The patient experience acute myocardial infarction ( AMI : STEMI NSTEMI ) within 72 hour procedure either CKMB Troponin return within 2X ULN . Patient leave ventricular ejection fraction &lt; 40 % Patient unprotected leave main coronary disease ≥50 % stenosis The target vessel totally occlude ( TIMI Flow 0 1 ) Target lesion involve bifurcation ( lesion side branch ≥ 1.5 mm diameter contain ≥ 50 % stenosis ) . Target lesion locate within bypass graft Target lesion possible definite thrombus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>